← All companies ← ONIT Manual ONT → ← OABI Life Sciences Tools & Services PACB →
ONMD, OneMedNet Corp
OneMedNet is a global provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data.
OneMedNet's innovative solutions connect healthcare providers and patients satisfying a crucial need within the life sciences field offering direct access to clinical images and the associated contextual patient record.
OneMedNet's innovative technology proved the commercial and regulatory viability of imaging Real World Data (as defined below), an emerging market, and provides regulatory-grade image-centric iRWDTM that exactly matches OneMedNet's life science partners case selection protocols and paves the way for Real World Evidence (as defined below).
The business
What it sells, where the money comes from, the kind of company it is.
The business in brief
read the 10-K →What this business is and what moves its needle, from its own SEC filings.
- Situation
- Unprofitable. No meaningful revenue yet; the record is the cash on hand against the burn. Distress / turnaround. Thin interest coverage, or operating cash burned against real debt, across the record. The balance sheet carries this situation; the debt schedule sets the clock.
- What moves the needle
- Operating margin has run around −711% through the cycle on a −37% gross margin, the operating line deeply negative — so the lever is the path to a margin at all: revenue growth against the cost curve and the cash runway, not the level of a margin that isn't there yet. Stock-based pay runs about 144% of sales, a real and recurring claim on owners that the GAAP margin understates. On its own account, the filing leans hardest on pricing power & competition, set against the numbers in what the filing emphasizes, below.
Every line is arithmetic on the company's filings, shown in full in the sections below.
The record
Ten years of arithmetic, read across the cycle.
The record, 2022–2025
realized figures from each filing · older years to the left| 2022’22 | 2023’23 | 2024’24 | 2025’25 | TTMTTMMar 2026 | |
|---|---|---|---|---|---|
| Income statement | |||||
| $1M | $1M | $643K | $1M | $1M | RevenueRevenue |
| −31% | −13% | −44% | −37% | −50% | Gross marginGross mgn |
| 417% | 347% | n/m | 469% | 493% | SG&A / revenueSG&A/rev |
| 138% | 202% | 228% | 111% | 112% | R&D / revenueR&D/rev |
| ($8M) | ($7M) | ($10M) | ($10M) | ($10M) | Operating incomeOp. inc. |
| −669.1% | −671.2% | n/m | −711.3% | −758.3% | Operating marginOp. mgn |
| ($30M) | ($34M) | ($10M) | ($3M) | ($3M) | Net incomeNet inc. |
| Cash flow & returns | |||||
| ($5M) | ($5M) | ($7M) | ($8M) | ($7M) | Operating cash flowOp. cash |
| $25K | $28K | $57K | $65K | $64K | DepreciationDeprec. |
| $24M | $27M | $2M | ($7M) | ($6M) | Working capital & otherWC & other |
| $58K | $44K | $51K | $13K | $10K | CapexCapex |
| 5.0% | 4.3% | 7.9% | 1.0% | 0.8% | Capex / revenueCapex/rev |
| ($5M) | ($5M) | ($7M) | ($8M) | ($7M) | Owner earningsOwner earn. |
| −412.9% | −473.6% | n/m | −553.1% | −546.4% | Owner earnings marginOE mgn |
| ($5M) | ($5M) | ($7M) | ($8M) | ($7M) | Free cash flowFCF |
| −412.9% | −473.6% | n/m | −553.1% | −546.4% | Free cash flow marginFCF mgn |
| Balance sheet | |||||
| $271K | $47K | $172K | $585K | $233K | Cash & investmentsCash+inv |
| $19K | $152K | $213K | $495K | $697K | ReceivablesReceiv. |
| $1M | $5M | $6M | $3M | $4M | Accounts payablePayables |
| ($1M) | ($5M) | ($6M) | ($3M) | ($3M) | Operating working capitalOper. WC |
| $391K | $365K | $4M | $2M | $1M | Current assetsCur. assets |
| $26M | $14M | $19M | $5M | $5M | Current liabilitiesCur. liab. |
| 0.0× | 0.0× | 0.2× | 0.4× | 0.3× | Current ratioCurr. ratio |
| $1M | $464K | $4M | $2M | $2M | Total assetsAssets |
| $2M | $465K | $12M | $1M | $2M | Total debtDebt |
| $1M | $418K | $12M | $609K | $1M | Net debt / (cash)Net debt |
| -19.1× | -623.0× | -65.3× | -144.3× | -217.3× | Interest coverageInt. cov. |
| ($26M) | ($13M) | ($16M) | ($3M) | ($4M) | Shareholders’ equityEquity |
| 161.8% | 144.5% | 97.7% | 149.5% | 171.1% | Stock comp / revenueSBC/rev |
| Per share | |||||
| 7.9M | 7.3M | 28.1M | 44.5M | 55.3M | Shares out (diluted)Shares |
| $0.15 | $0.14 | $0.02 | $0.03 | $0.02 | Revenue / shareRev/sh |
| $-3.83 | $-4.65 | $-0.36 | $-0.06 | $-0.06 | EPS (diluted)EPS |
| $-0.60 | $-0.66 | $-0.25 | $-0.17 | $-0.13 | Owner earnings / shareOE/sh |
| $-0.60 | $-0.66 | $-0.25 | $-0.17 | $-0.13 | Free cash flow / shareFCF/sh |
| $0.01 | $0.01 | $0.00 | $0.00 | $0.00 | Cap. spending / shareCapex/sh |
| $-3.32 | $-1.85 | $-0.57 | $-0.07 | $-0.07 | Book value / shareBVPS |
Share counts before 2023 are restated ×2 for a stock split, so per-share figures sit on one basis.
The diluted share count moved ×3.86 into 2024 — shares issued, not a split the totals corroborate — and the per-share figures carry the counts as filed.
The diluted share count moved ×1.59 into 2025 — shares issued, not a split the totals corroborate — and the per-share figures carry the counts as filed.
| 3-yr | 5-yr | |
|---|---|---|
| Revenue / share | −40.5%/yr | −40.5%/yr (3-yr) |
| Capital spending / share | −65.8%/yr | −65.8%/yr (3-yr) |
The record, charted
FY2022–2025Each measure over its full record; the current point and the worst year marked. Share counts on the current split basis.
Owner earnings vs. net income
Owner earningsNet incomeThe accountant's number, and the cash an owner can take; the gap is the tell.
Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.
In fiscal 2025 the business reported a $3M loss but ($8M) of owner earnings: $5M less than the profit line, taken out by capital spending and the timing of cash.
| FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|
| Reported net income | ($3M) | ($10M) | ($34M) | ($30M) |
| Depreciation & amortizationnon-cash charge added back | +$65K | +$57K | +$28K | +$25K |
| Stock-based compensationreal costnon-cash, but a real cost | +$2M | +$628K | +$1M | +$2M |
| Working capital & othertiming of cash in and out, other non-cash items | −$7M | +$2M | +$27M | +$24M |
| Cash from operations | ($8M) | ($7M) | ($5M) | ($5M) |
| Capital expenditurecash put back in to keep running and to grow | −$13K | −$51K | −$44K | −$58K |
| Owner earnings | ($8M) | ($7M) | ($5M) | ($5M) |
| Owner-earnings marginowner earnings ÷ revenue | -553% | -1089% | -474% | -413% |
Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position . The cash-flow statement also adds stock comp back as non-cash, but it is a real cost paid in shares; counted as the expense it is (less $2M), owner earnings is nearer ($10M).
Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.
Quality & stewardship
Returns, the balance sheet, capital allocation, and pay.
Owner’s Scorecard
“We are in the process of remediating the identified material weaknesses in our internal controls, but we are unable at this time to estimate when the remediation efforts will be completed.”
The figures below are only as sound as the controls that produced them. read the note →
Will it survive?
- Can it pay its interest? -144.3×Does not cover its interestOperating income ($10M) ÷ interest expense $67K
What this means
A full year of operating profit didn't cover the interest bill. This is the zombie zone: the business depends on refinancing, asset sales, or forbearance to service its debt.
- Net debt against an operating lossCash $585K − debt $2M
What this means
Netting $585K of cash and short-term investments against $2M of debt leaves $915K owed, with no operating profit this year to measure it against — understand that combination before anything else about the company. Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.
- Negative, funded by othersDSO 133 + DIO 0 − DPO 627 days
What this means
Days cash is tied up between paying suppliers and collecting from customers. A negative cycle is a quiet moat: suppliers and customers fund the operation (Buffett's “float”), the company grows on other people's money. (Little or no inventory, a services / asset-light model, so the inventory leg is ~0.)
Is it a good business?
- Not meaningful hereInvested capital ($2M) = debt $2M + equity ($3M) − cashIndustry peers: median 8%
What this means
Invested capital is near zero or negative, usually years of buybacks pulling equity down. ROIC explodes or flips sign and stops meaning anything. Judge this one on Owner Earnings instead.
- Owner-earnings margin -553%Consumes cash through the cycle4-yr median margin, range -1089%–-413%; latest ($8M) = operating cash ($8M) − maintenance capex $13KIndustry peers: median 4%
What this means
What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's -553% of revenue this year, a -553% median across 4 years. Treating stock comp as the real expense it is (less $2M of SBC) leaves ($10M).
- Loss, and burning cashNet income ($3M) · cash from operations ($8M)
In the filing’s words The filing discloses a material weakness in its financial controls — the reported numbers here, and the record built on them, are only as reliable as the controls that produced them.
What this means
The company reported a net loss, so a conversion ratio isn't meaningful. What matters then is whether operations still threw off cash, here, they did not.
How is the cash used?
- Not enough data
What this means
The filing data didn't include the inputs for this check.
- Investing or harvesting? 0.20×HarvestingCapex $13K ÷ depreciation $65K
What this means
Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.
Graham’s defensive tests · 0 of 3 met
Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.
- Adequate size MissRevenue ≥ $2B · $1M
What this means
Big enough to weather a storm. Graham's 1972 floor was ~$100M of sales (≈ $700M today); we use a $2B revenue line as a conservative modern stand-in.
- Strong liquidity MissCurrent ratio ≥ 2× · 0.43×
What this means
Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.
- Conservative debt MissDebt ≤ working capital · $2M vs ($3M) WC
What this means
Graham's rule that borrowings not exceed net current assets. Capital-heavy and buyback-heavy firms routinely fail it, read it next to interest coverage, not alone.
- Moderate price —P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
What this means
Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are $-0.29/share (latest year $-0.05), the averaged base the calculator's gate runs on, and book value is $-0.05/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.
Durability & moat, 2022–2025
Whether the record’s returns held, and what the capital reinvested earned.
- Profitable years 0 of 4
What this means
Lost money in 4 year(s), look at what happened there before trusting the average.
- Operating margin −670% → −1103% (2-yr avg ends)
What this means
Through the cycle the operating margin slipped — about −670% early to −1103% lately, median −711% — competition or costs are biting in.
- Worst year 2024 · −1493.8% op. margin
What this means
Operations went underwater in 2024, understand why before trusting the good years.
Does AI threaten the moat?
Moderate contestabilityAI is likely to reshape costs and some products here without clearly contesting or sparing the core moat; how the company itself frames it is the tell.
The filing positions AI as something the company uses, not something it fears.
“Today, life science companies, including pharmaceutical companies, artificial intelligence ("AI") developers, medical device businesses, and clinical research organizations, share the same widespread challenge in obtaining insight-rich, high-quality patient data that explicitly m…”
The question is whether a moat the record shows as durable outlasts a technology that lowers the cost of part of what the firm sells. The durability is read in the record above, the filing's own framing of AI beside it; the industry label decides nothing on its own.
Read from the filing's own risk factors, paired with the industry's structure under its SIC code; the durability is read above, the price below.
All figures as filed; the source filing is linked above.
Current Position
as of the latest quarter, Mar 31, 2026Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.
- Cash & short-term investments$233K
- Receivables$697K
- Other current assets$530K
- Debt due within a year$837K
- Accounts payable$4M
- Other current liabilities$577K
From the company's latest filing.
Management, ownership & pay
From the proxy: how much of the business the people running it own, and how they are paid.
- Stock-based compensation$2M
The slice of the business handed to employees in shares this year, 150% of revenue. Buffett's oldest accounting fight: this is compensation, compensation is an expense, real whether or not the headline earnings admit it. One trap: the cash-flow statement adds SBC back, so the operating cash, and the owner earnings drawn from it, are flattered by exactly this amount; counted as the cost it is, what an owner keeps is lower.
Inverting the record
Invert: instead of why OneMedNet Corp is a good business, the question is what would make owning it a mistake, and whether those marks are in the record. Disconfirming tests across 2022–2025.
1 of the 3 tests turned up something to look into; the other 2 came back clean.
- Look hereDid receivables and inventory outpace sales?2% → 53% of sales
Receivables and inventory grew from $19K to $697K while revenue grew 14%: working capital is climbing faster than sales (2% of revenue then, 53% now). That can mean customers paying slower, stock building up, or revenue pulled forward. The filing's cash-flow and receivables notes say which.
- Did debt outgrow the business?
- Are "one-time" charges a yearly habit?
Each test is read from the filings and is noisy alone; a flag can mark a cyclical trough or a year of heavy investment as easily as a problem. The filing says which.
What an owner would ask, FY2025
read the 10-K →- Which reported numbers are a judgment call?Management names Revenue recognition as critical estimates
each rests partly on management's judgment; the filing's note sets out the assumptionsverify →
The questions the record and the charts do not answer on their own; each carries the figure and the place to look.
Peers, Life Sciences Tools & Services
The same industry, side by side on owner economics. Each figure is a through-cycle median, so a peak or trough year can’t distort it; the group median at the foot is the line to read each against.
| Company | Revenue | Gross margin | Op. margin | ROIC | Owner earn. margin |
|---|---|---|---|---|---|
| MEDPMedpace Holdings | $2.5B | — | 17.6% | 27% | 22% |
| NEONeoGenomics Inc. | $727M | 42% | -8.5% | -7% | -4% |
| MGMistras Group Inc | $724M | 32% | 2.9% | 3% | 4% |
| WLDNWilldan Group Inc. | $682M | 35% | 4.9% | 8% | 4% |
| EXPOExponent | $582M | — | 20.8% | 44% | 22% |
| NRCNRC Health | $137M | — | 29.3% | 47% | 21% |
| OABIOmniAb Inc. | $19M | — | -203.2% | -18% | -35% |
| ONMDOneMedNet Corp | $1M | -34% | -691.3% | — | -513% |
| Group median | — | 33% | 3.9% | — | 4% |
The price
What a price has to assume.
What the price implies
reverse-DCFOneMedNet Corp is profitable, but owner earnings are negative this year because capital spending currently outruns operating cash, a build-out, so the owner-earnings reverse-DCF has no positive base to grow. We read the price from both ends instead: type a price to see the steady-state profitability it demands, then set the mature margin you would believe and weigh the two against each other. Nothing leaves your browser unless you enter it in your notebook.
Revenue, delivered0%/yr’22→’25
Enter a price to run it.
A dated snapshot of the price you typed, the assumptions you set, and what the page showed for them. A snapshot is never edited after it is saved. Your notebook is yours alone — the commitment states what is stored and what we will never do.
Two reads of one future. From your price: the owner earnings the company must reach, valued at a mature multiple and discounted back at your rate, expressed as the margin it implies on revenue grown at your rate. From your belief: the mature margin you would credit, set on the dial above. When the margin the price demands runs above the one you would believe, you are paying for a future taken on faith. For a deep cyclical at a trough, normalized through-cycle earnings are the better lens; this mode is for the genuinely unprofitable, and for the profitable business whose capital spending currently outruns its cash.
Manual order: ← ONIT its page in the Manual ONT →
Industry order: ← OABI the Life Sciences Tools & Services chapter PACB →